OBJECTIVE: To evaluate the results of stereotactic radiosurgery treating @entity5513 secondary to type 2 @entity4786 . METHODS: A retrospective review of 122 type 2 @entity5513 consecutively treated in 96 @entity1 . Tumour control was assessed by recourse to surgical intervention, by serial radiological imaging, and by the calculation of relative growth ratios in @entity1 (n=29) habouring untreated @entity5 to act as internal controls. Hearing function was assessed with Gardner-Robertson grades and with averaged pure tone audiogram thresholds. Other complications are detailed. RESULTS: Applying current techniques, eight years after radiosurgery it was estimated that 20% of @entity1 will have undergone surgery for their @entity5 , 50% will have radiologically controlled @entity5 , and in 30% there will be some variable concern about @entity5 control, but up to that time they will have been managed conservatively. Relative growth ratios one and two years after treatment indicate that radiosurgery confers a significant (p=0.01) advantage over the natural history of the disease. Analysis of these ratios beyond two years was precluded by the need to intervene and radiosurgically treat the contralateral control @entity5 in more than 50% of the cases. This growth control was achieved with 40% of @entity1 retaining their Gardner-Robertson hearing grades three years after treatment, (40% having some deterioration in grade, 20% becoming deaf). Pure tone audiogram results suggest some progressive long term @entity393 , although interpretation of this is difficult. @entity16 occurred in 5% and 2%. CONCLUSIONS: Radiosurgery is a valuable minimally invasive alternative treatment for these @entity5 . For most @entity1 , it controls growth or defers the need for surgery, or both. There is a price in terms of hearing function, although this may compare favourably with the @entity2319 associated with the natural history of the disease, and with surgery. In deciding on therapy, @entity1 should be aware of this treatment option.

Clinical experience with gamma knife stereotactic radiosurgery in the management of XXXX secondary to type 2 @entity4786 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5513 :: ('MESH:D009464', 'Disease') :: ['vestibular schwannomas', 'neurofibromatosis vestibular schwannomas'] @entity5 :: ('MESH:D009369', 'Disease') :: ['contralateral tumours', 'tumours', 'tumour'] @entity16 :: ('MESH:D009422', 'Disease') :: ['Facial and trigeminal neuropathy'] @entity2319 :: ('MESH:D003638', 'Disease') :: ['deafness'] @entity4786 :: ('MESH:D017253', 'Disease') :: ['neurofibromatosis'] @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss']
@entity5513 :: (MESH:D009464,Disease) :: ['vestibular schwannomas']
